These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 2495745

  • 1. The thrombolytic effects of native tissue-type plasminogen activator (AK-124) on experimental canine coronary thrombosis.
    Tomaru T, Uchida Y, Sonoki H, Tsukamoto M, Sugimoto T.
    Angiology; 1989 May; 40(5):429-35. PubMed ID: 2495745
    [Abstract] [Full Text] [Related]

  • 2. Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.
    Nicolini FA, Nichols WW, Saldeen TG, Mehta JL.
    Cardiovasc Res; 1991 Apr; 25(4):283-9. PubMed ID: 1909212
    [Abstract] [Full Text] [Related]

  • 3. Heparin requirement in tissue-type plasminogen activator-induced experimental coronary thrombolysis: comparison with urokinase-induced coronary thrombolysis.
    Susawa T, Yui Y, Hattori R, Takahashi M, Aoyama T, Takatsu Y, Sakaguchi K, Yui N, Kawai C.
    Jpn Circ J; 1987 Apr; 51(4):431-5. PubMed ID: 2441082
    [Abstract] [Full Text] [Related]

  • 4. [An experimental study of local fibrinolysis using tissue plasminogen activator and urokinase in a canine common carotid artery thrombus model].
    Kawakami K, Takahashi A, Yoshimoto T.
    No To Shinkei; 1990 Feb; 42(2):193-201. PubMed ID: 2113401
    [Abstract] [Full Text] [Related]

  • 5. Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.
    Ziskind AA, Gold HK, Yasuda T, Kanke M, Guerrero JL, Fallon JT, Saito T, Collen D.
    Circulation; 1989 Feb; 79(2):393-9. PubMed ID: 2492455
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Systemic lysis protects against the effects of platelet activation during coronary thrombolysis.
    Fitzgerald DJ, Hanson M, FitzGerald GA.
    J Clin Invest; 1991 Nov; 88(5):1589-95. PubMed ID: 1939647
    [Abstract] [Full Text] [Related]

  • 8. A canine model of coronary artery thrombosis with superimposed high grade stenosis for the investigation of rethrombosis after thrombolysis.
    Yasuda T, Gold HK, Fallon JT, Leinbach RC, Garabedian HD, Guerrero JL, Collen D.
    J Am Coll Cardiol; 1989 May; 13(6):1409-14. PubMed ID: 2495318
    [Abstract] [Full Text] [Related]

  • 9. Comparison of intravenous bolus injection or continuous infusion of recombinant single chain urokinase-type plasminogen activator (saruplase) for thrombolysis. A canine model of combined coronary arterial and femoral venous thrombosis.
    Rapold HJ, Wu ZM, Stassen T, Van de Werf F, Collen D.
    Blood; 1990 Oct 15; 76(8):1558-63. PubMed ID: 2119830
    [Abstract] [Full Text] [Related]

  • 10. Simultaneous administration of thromboxane A2- and serotonin S2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis.
    Golino P, Ashton JH, McNatt J, Glas-Greenwalt P, Yao SK, O'Brien RA, Buja LM, Willerson JT.
    Circulation; 1989 Apr 15; 79(4):911-9. PubMed ID: 2494005
    [Abstract] [Full Text] [Related]

  • 11. Recombinant single-chain urokinase-type plasminogen activator (rscu-PA) induces thrombolysis and systemic fibrinolysis in a canine model of coronary artery thrombosis.
    Söhngen W, Mickelson JK, Simpson PJ, Lucchesi BR.
    Thromb Res; 1988 Jul 01; 51(1):63-74. PubMed ID: 3137691
    [Abstract] [Full Text] [Related]

  • 12. Enhanced myocardial salvage by combined treatment with recombinant single-chain urokinase-type plasminogen activator and recombinant human superoxide dismutase in a canine coronary thrombosis model.
    Fincke U, Schneider J, Friderichs E, Giertz H, Flohé L.
    Arzneimittelforschung; 1988 Jan 01; 38(1):138-42. PubMed ID: 3365272
    [Abstract] [Full Text] [Related]

  • 13. Comparative studies of thrombolysis with single-chain and two-chain recombinant tissue-type plasminogen activators in canine coronary thrombosis.
    Yokoyama M, Ichikawa Y, Yatani A, Matsui K, Nakahara H, Kaneko M, Sakurama T, Ueshima S, Matsuo O.
    J Cardiovasc Pharmacol; 1996 Oct 01; 28(4):571-5. PubMed ID: 8891884
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the thrombolytic efficacy of defibrase and urokinase on canine coronary artery thrombosis and the mechanism of urokinase-induced hemorrhage.
    Huang DX, Song A, Yang X, Wang S.
    Acta Cardiol; 1987 Oct 01; 42(4):249-61. PubMed ID: 3499037
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Combined thrombolytic effects of tissue-plasminogen activator and a fibrinogen-degradation product peptide 6A or iloprost.
    Nichols WW, Nicolini FA, Saldeen TG, Mehta JL.
    J Cardiovasc Pharmacol; 1991 Aug 01; 18(2):231-6. PubMed ID: 1717784
    [Abstract] [Full Text] [Related]

  • 18. Thrombolysis with recombinant human single-chain urokinase-type plasminogen activator (rscu-PA): dose-response in dogs with coronary artery thrombosis.
    Van de Werf F, Jang IK, Collen D.
    J Cardiovasc Pharmacol; 1987 Jan 01; 9(1):91-3. PubMed ID: 2434801
    [Abstract] [Full Text] [Related]

  • 19. A thrombosis model for evaluating thrombolytic agents in the guinea-pig: comparison of t-PA, scu-PA and a novel thrombolytic agent, staphylokinase, on thrombolytic activity.
    Hirata Y, Umemura K, Takiguchi Y, Uematsu T, Nakashima M.
    Blood Coagul Fibrinolysis; 1993 Aug 01; 4(4):569-75. PubMed ID: 7692999
    [Abstract] [Full Text] [Related]

  • 20. Prevention of reocclusion following tissue type plasminogen activator-induced thrombolysis by the RGD-containing peptide, echistatin, in a canine model of coronary thrombosis.
    Holahan MA, Mellott MJ, Garsky VM, Shebuski RJ.
    Pharmacology; 1991 Aug 01; 42(6):340-8. PubMed ID: 1946598
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.